Biotechnology · Los Angeles, California, United States
$11.18
+1.73% (+$0.19)2026-07-09
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Net Income-$10.1M
EPS$-0.18
Market Cap$592.7M
Price Performance
Historical data including institutional events
Company Profile
I
Ilya Rachman
CEO & Executive Director
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
The companyâ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
